259 related articles for article (PubMed ID: 35228448)
1. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
Miyasaka K
Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
[TBL] [Abstract][Full Text] [Related]
2. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
Andersen A; Knop FK; Vilsbøll T
Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
[TBL] [Abstract][Full Text] [Related]
3. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
Paquot N
Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
[TBL] [Abstract][Full Text] [Related]
4. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
5. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim HS; Jung CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
[TBL] [Abstract][Full Text] [Related]
6. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
Blakely KK; Weaver K
Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
[TBL] [Abstract][Full Text] [Related]
8. Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
Karásek D
Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
[TBL] [Abstract][Full Text] [Related]
9. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
[TBL] [Abstract][Full Text] [Related]
10. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
11. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
12. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
13. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
15. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
16. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide in type 2 diabetes.
Anderson SL; Beutel TR; Trujillo JM
J Diabetes Complications; 2020 Apr; 34(4):107520. PubMed ID: 31952996
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
19. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
20. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Granhall C; Donsmark M; Blicher TM; Golor G; Søndergaard FL; Thomsen M; Bækdal TA
Clin Pharmacokinet; 2019 Jun; 58(6):781-791. PubMed ID: 30565096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
